The role of nitric oxide in tumour progression

Nature Reviews Cancer

Volumn 6, Issue 7, 2006, Pages 521-534

  Fukumura, Dai ^a   Kashiwagi, Satoshi ^a   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; COMBRETASTATIN A4; CYCLOOXYGENASE 2 INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE V INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SILDENAFIL;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL MATURATION; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; NITROSYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SIGNAL TRANSDUCTION;

EID: 33745559710     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1910     Document Type: Review

References (168)

1. Nathan, C. & Xie, O. W. Nitric oxide synthases: roles, tolls, and controls. Cell 78, 915-918 (1994).
2. Sessa, W. C. eNOS at a glance. J. Cell Sci. 117, 2427-2429 (2004).
3. Friebe, A. & Koesling, D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ. Res. 93, 96-105 (2003).
4. Stamler, J. S., Lamas, S. & Fang, F. C. Nitrosylation: the prototypic redox-based signaling mechanism. Cell 106, 675-683 (2001).
5. Lala, P. K. & Chakraborty, C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol. 2, 149-156 (2001).
6. Wink, D. A. et al. The role of nitric oxide chemistry in cancer treatment. Biochemistry Mosc. 63, 802-809 (1998).
7. Ekmekcioglu, S., Tang, C. H. & Grimm, E. A. NO news is not necessarily good news in cancer. Curr. Cancer Drug Targets 5, 103-115 (2005).
8. Hofseth, L. J., Hussain, S. P., Wogan, G. N. & Harris, C. C. Nitric oxide in cancer and chemoprevention. Free Radic. Biol. Med. 34, 955-968 (2003).
9. Crowell, J. A., Steele, V. E., Sigman, C. C. & Fay, J. R. Is inducible nitric oxide synthase a target for chemoprevention? Mol. Cancer Ther. 2, 815-823 (2003).
10. Min/+ mice by inhibiting nitric oxide production. Cancer Res. 61, 8357-8360 (2001).
11. Nam, K. T. et al. Decreased Helicobacter pylori associated gastric carcinogenesis in mice lacking inducible nitric oxide synthase. Gut 53, 1250-1255 (2004).
12. Kisley, L. R. et al. Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Res. 62, 6850-6856 (2002).
13. Ellies, L. G. et al. Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase. Int. J. Cancer 106, 1-7 (2003).
14. Rao, C. V. et al. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res. 62, 165-170 (2002). References 10-14 show iNOS-mediated tumorigenesis in various carcinogenesis models.
15. Ambs, S. et al. p53 and vascularendothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nature Med. 4, 1371-1376 (1998). Demonstration of iNOS-induced VEGF expression and determination of anti- or pro-tumour effect of NO by p53 status.
16. Zhang, J., Dawson, V. L., Dawson, T. M. & Snyder, S. H. Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science 263, 687-689 (1994).
17. Xu, W., Liu, L., Smith, G. C. M. & Charles, I. G. Nitric oxide upregulates expression of DNA-PKcs to protect cells from DNA-damaging anti-tumour agents. Nature Cell Biol. 2, 339-345 (2000).
18. Dhar, A. et al. Nitric oxide does not mediate but inhibits transformation and tumor phenotype. Mol. Cancer Ther. 2, 1285-1293 (2003).
19. Min/+ mouse. Gastroenterology 121, 889-899 (2001).
20. Hussain, S. P. et al. Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Res. 64, 6849-6853 (2004). References 18-20 show prevention of tumorigenesis by iNOS in various carcinogenesis models.
21. Jenkins, D. C. et al. Roles of nitric oxide in tumor growth. Proc. Natl Acad. Sci. USA 92, 4392-4396 (1995). Demonstration of the induction of angiogenesis and tumour growth by iNOS transduction.
22. Yamaguchi, S. et al. Glioma tumourgenicity is decreased by iNOS knockout: experimental studies using the C6 striatal implantation glioma model. Br. J. Neurosurg. 16, 567-572 (2002).
23. Orucevic, A. et al. Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Int. J. Cancer 81, 889-896 (1999).
24. Siegert, A., Rosenberg, C., Schmitt, W. D., Denkert, C. & Hauptmann, S. Nitric oxide of human colorectal adenocarcinoma cell lines promotes tumour cell invasion. Br. J. Cancer 86, 1310-1315 (2002).
25. Jadeski, L. C., Chakraborty, C. & Lala, P. K. Nitric oxide-mediated promotion of mammary tumour cell migration requires sequential activation of nitric oxide synthase, guanylate cyclase and mitogen-activated protein kinase. Int. J. Cancer 106, 496-504 (2003).
26. Barreiro Arcos, M. L. et al. Inducible nitric oxide synthase-mediated proliferation of a T lymphoma cell line. Nitric Oxide 8, 111-118 (2003).
27. Zhang, X. M. & Xu, Q. Metastatic melanoma cells escape from immunosurveillance through the novel mechanism of releasing nitric oxide to induce dysfunction of immunocytes. Melanoma Res. 11, 559-567 (2001).
28. Nunokawa, Y. & Tanaka, S. Interferon-γ inhibits proliferation of rat vascular smooth muscle cells by nitric oxide generation. Biochem. Biophys. Res. Commun. 188, 409-415 (1992).
29. Xie, K. et al. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J. Exp. Med. 181, 1333-1343 (1995). Demonstration of decreased experimental metastasis by transduction of iNOS gene into tumour cells.
30. Juang, S. H. et al. Suppression of tumorigenicity and metastasis of human renal carcinoma cells by infection with retroviral vectors harboring the murine inducible nitric oxide synthase gene. Hum. Gene Ther. 9, 845-854(1998).
31. Le, X., Wei, D., Huang, S., Lancaster, J. R. Jr., & Xie, K. Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its up-regulation of protumor factors. Proc. Natl Acad. Sci. USA 102, 8758-8763 (2005).
32. Shi, Q. et al. Direct correlation between nitric oxide synthase II inducibility and metastatic ability of UV-2237 murine fibrosarcoma cells carrying mutant p53. Cancer Res. 59, 2072-2075 (1999).
33. Radomski, M. W., Jenkins, D. C., Holmes, L. & Moncada, S. Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res. 51, 6073-6078 (1991).
34. Gasic, G. J., Gasic, T. B. & Stewart, C. C. Antimetastatic effects associated with platelet reduction. Proc. Natl Acad. Sci. USA 61, 46-52 (1968).
35. Kisucka, J. et al. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc. Natl Acad. Sci. USA 103, 855-860 (2006).
36. Im, J. H. et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res. 64, 8613-8619 (2004).
37. Wang, B. et al. A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis. Oncogene 22, 1771-1782 (2003).
38. Xie, K. & Huang, S. Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency. Free Radic. Biol. Med. 34, 969-986 (2003).
39. Dong, Z. et al. Activation of inducible nitric oxide synthase gene in murine macrophages requires protein phosphatases 1 and 2A activities. J. Leukoc. Biol. 58, 725-732 (1995).
40. Liu, C. Y. et al. Increased level of exhaled nitric oxide and up-regulation of inducible nitric oxide synthase in patients with primary lung cancer. Br. J. Cancer 78, 534-541 (1998).
41. Muerkoster, S. et al. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1β. Cancer Res. 64, 1331-1337 (2004).
42. Wei, D. et al. Direct demonstration of negative regulation of tumor growth and metastasis by host-inducible nitric oxide synthase. Cancer Res. 63, 3855-3859 (2003).
43. Konopka, T. E. et al. Nitric oxide synthase II gene disruption: implications for tumor growth and vascular endothelial growth factor production. Cancer Res. 61, 3182-3187 (2001).
44. Shi, Q. et al. Influence of nitric oxide synthase II gene disruption on tumor growth and metastasis. Cancer Res. 60, 2579-2583 (2000). Demonstrates that tumour-cell sensitivity to NO defines the effect of host iNOS on tumour growth and metastasis.
45. Gauthier, N. et al. Tumour-derived and host-derived nitric oxide differentially regulate breast carcinoma metastasis to the lungs. Carcinogenesis 25, 1559-1565 (2004).
46. Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases: from genes to function to therapy. Nature 407, 249-257 (2000).
47. Oliveira, C. J. R. et al. Nitric oxide and cGMP activate the Ras-MAP kinase pathway-stimulating protein tyrosine phosphorylation in rabbit aortic endothelial cells. Free Radic. Biol. Med. 35, 381-396 (2003).
48. Kawasaki, K. et al. Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol. Cell. Biol. 23, 5726-5737 (2003).
49. Zaragoza, C. et al. Activation of the mitogen activated protein kinase extracellular signal-regulated kinase 1 and 2 by the nitric oxide-cGMP-cCMP- dependent protein kinase axis regulates the expression of matrix metalloproteinase 13 in vascular endothelial cells. Mol. Pharmacol. 62, 927-935 (2002).
50. Heller, R., Polack, T., Grabner, R. & Till, U. Nitric oxide inhibits proliferation of human endothelial cells via a mechanism independent of cGMP. Atherosclerosis 144, 49-57 (1999).
51. Pipili-Synetos, E., Sakkoula, E. & Maagoudakis, M. E. Nitric oxide is involved in the regulation of angiogenesis. Br. J. Pharmacol. 108, 855-857 (1993).
52. Lau, Y.-T. & Ma, W.-C. Nitric oxide inhibits migration of cultured endothelial cells. Biochem. Biophys. Res. Comm. 221, 670-674 (1996).
53. Jones, M. K., Tsugawa, K., Tarnawski, A. S. & Baatar, D. Dual actions of nitric oxide on angiogenesis: possible roles of PKC, ERK, and AP-1. Biochem. Biophys. Res. Comm. 318, 520-528 (2004).
54. Ridnour, L. A. et al. Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc. Natl Acad. Sci. USA 102, 13147-13152 (2005). References 53 and 54 show dose-dependent biphasic effects of NO on angiogenesis.
55. Fukumura, D. & Jain, R. K. Role of nitric oxide in angiogenesis and microcirculation in tumors. Cancer Metastasis Rev. 17, 77-89 (1998).
56. Papapetropoulos, A., Garcia-Cardena, G., Madri, J. A. & Sessa, W. C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. 100, 3131-3139 (1997).
57. Fukumura, D. et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc. Natl Acad. Sci. USA 98, 2604-2609 (2001). Demonstrates that NO that is derived from eNOS mediates VEGF-induced angiogenesis and vascular hyperpermeability in vivo.
58. Babaei, S. et al. Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide. Am. J. Pathol. 162, 1927-1936 (2003).
59. Urbich, C. et al. Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB J. 16, 706-708 (2002).
60. Isenberg, J. S. et al. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc. Natl Acad. Sci. USA 102, 13141-13146 (2005).
61. Gratton, J. P. et al. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 4, 31-39 (2003). Demonstration of the reduction of angiogenesis, vascular permeability and tumour growth by cavtratin, a cell-permeable peptide that is derived from caveolin 1.
62. Kashiwagi, S. et al. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J. Clin. Invest. 115, 1816-1827 (2005). Demonstrates that NO that is derived from eNOS mediates recruitment of perivascular cells to angiogenic vessels in vivo.
63. Chin, K. et al. Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells. Oncogene 15, 437-442 (1997).
64. Ziche, M. et al. Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. Circ. Res. 80, 845-852 (1997).
65. Sandau, K. B., Zhou, J., Kietzmann, T. & Brune, B. Regulation of the hypoxia-inducible factor 1α by the inflammatory mediators nitric oxide and tumor necrosis factor-α in contrast to desferroxamine and phenylarsine oxide. J. Biol. Chem. 276, 39805-39811 (2001).
66. Kimura, H. et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 95, 189-197 (2000).
67. Kasuno, K. et al. Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MARK and phosphatidylinositol 3-kinase signaling. J. Biol. Chem. 279, 2550-2558 (2004).
68. Metzen, E., Zhou, J., Jelkmann, W., Fandrey, J. & Brune, B. Nitric oxide impairs normoxic degradation of HIF-1α by inhibition of prolyl hydroxylases. Mol. Biol. Cell 14, 3470-3481 (2003).
69. Sogawa, K. et al. Inhibition of hypoxia-inducible factor 1 activity by nitric oxide donors in hypoxia. Proc. Natl Acad. Sci. USA 95, 7368-7373 (1998).
70. Huang, L. E., Willmore, W. G., Gu, J., Goldberg, M. A. & Bunn, H. F. Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide, implications for oxygen sensing and signaling. J. Biol. Chem. 274, 9038-9044 (1999).
71. Liu, Y. et al. Carbon monoxide and nitric oxide suppress the hypoxic induction of vascular endothelial growth factor gene via the 5′ enhancer. J. Biol. Chem. 273, 15257-15262 (1998).
72. Genius, J. & Fandrey, J. Nitric oxide affects the production of reactive oxygen species in hepatoma cells: implications for the process of oxygen sensing. Free Radic. Biol. Med. 29, 515-521 (2000).
73. Thomas, D. D. et al. Hypoxic inducible factor 1α, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc. Natl Acad. Sci. USA 101, 8894-8899 (2004).
74. Pae, H. O., Oh, G. S., Choi, B. M., Kim, Y. M. & Chung, H. T. A molecular cascade showing nitric oxide-heme oxygenase-1-vascular endothelial growth factor-interleukin-8 sequence in human endothelial cells. Endocrinology 146, 2229-2238 (2005).
75. Quintero, M., Brennan, P. A., Thomas, G. J. & Moncada, S. Nitric oxide is a factor in the stabilization of hypoxia-inducible factor-1α in cancer: role of free radical formation. Cancer Res. 66, 770-774 (2006).
76. Matsunaga, T. et al. Angiostatin inhibits coronary angiogenesis during impaired production of nitric oxide. Circulation 105, 2185-2191 (2002).
77. Rafii, S., Lyden, D., Benezra, R., Hattori, K. & Heissig, B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nature Rev. Cancer 2, 826-835 (2002).
78. De Palma, M. et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8, 211-226 (2005).
79. Peters, B. A. et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nature Med. 11, 261-262 (2005).
80. Duda, D. G. et al. Evidence for bone marrow-derived endothelial cells incorporation into perfused blood vessels in tumors. Blood 107 2774-2776 (2006).
81. Aicher, A. et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nature Med. 9, 1370-1376 (2003). Demonstration of the role of eNOS in endothelial-progenitor-cell recruitment.
82. Marcet-Palacios, M. et al. Nitric oxide and cyclic GMP increase the expression of matrix metalloproteinase-9 in vascular smooth muscle. J. Pharmacol. Exp. Ther. 307, 429-436 (2003).
83. Gu, Z. et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297, 1186-1190 (2002).
84. Yu, J. et al. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc. Natl Acad. Sci. USA 102, 10999-11004 (2005).
85. Jain, R. K. Molecular regulation of vessel maturation. Nature Med. 9, 685-693 (2003).
86. Koike, N. et al. Tissue engineering: creation of long-lasting blood vessels. Nature 428, 138-139 (2004).
87. Furchgott, R. F. & Zawadzki, J. V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288, 373-376 (1980). Discovery of endothelial-cell-derived relaxing factor (NO).
88. Ignarro, L. J., Cirino, G., Casini, A. & Napoli, C. Nitric oxide as a signaling molecule in the vascular system: an overview. J. Cardiovasc. Pharmacol. 34, 879-886 (1999).
89. Fukumura, D., Yuan, F., Endo, M. & Jain, R. K. Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. Am. J. Pathol. 150, 713-725 (1997). Demonstrates that NO maintains blood flow, induces vascular permeability and inhibits leukocyte-endothelial interaction in tumours.
90. Andrade, S. P., Hart, I. R. & Piper, P. J. Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br. J. Pharmacol. 107, 1092-1095 (1992).
91. Tozer, G. M., Prise, V. E. & Chaplin, D. J. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res. 57, 948-955 (1997).
92. Swaroop, G. R., Malcolm, G. P., Kelly, P. A., Ritchie, I. & Whittle, I. R. Effects of nitric oxide modulation on tumour blood flow and microvascular permeability in C6 glioma. Neuroreport 9, 2577-2581 (1998).
93. Kubes, P. Nitric oxide affects microvascular permeability in the intact and inflamed vasculature. Microcirculation 2, 235-244 (1995).
94. Boughton-Smith, N. K., Evans, S. M., Laszlo, F., Whittle, B. J. R. & Moncada, S. The induction of nitric oxide synthase and intestinal vascular permeability by endotoxin in the rat. Br. J. Pharmacol. 110, 1189-1195 (1993).
95. Fujii, E., irie, K., Uchida, Y., Tsukahara, F. & Muraki, T. Possible role of nitric oxide in 5-hydroxytryptamine-induced increase in vascular permeability in mouse skin. Naunyn Schmiedebergs Arch. Pharmacol. 350, 361-364 (1994).
96. Nakano, S., Matsukado, K. & Black, K. L. Increased brain microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide. Cancer Res. 56, 4027-4031 (1996).
97. G-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice. Br. J. Cancer 73, 189-196 (1996).
98. Ramírez, M. M. et al. Platelet activating factor modulates microvascular permeability through nitric oxide synthesis. Microvasc. Res. 50, 223-234 (1995).
99. Mayhan, W. G. VEGF increases permeability of the blood-brain barrier via a nitric oxide synthase/cGMP-dependent pathway. Am. J. Physiol. 276, C1148-C1153 (1999).
100. Aramoto, H., Breslin, J. W., Pappas, P. J., Hobson, R. W. & Duran, W. N. Vascular endothelial growth factor stimulates differential signaling pathways in in vivo microcirculation. Am. J. Physiol. Heart Circ. Physiol. 287, H1590-H1598 (2004).
101. Maeda, H., Noguchi, Y., Sato, K. & Akaike, T. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn. J. Cancer Res. 85, 331-334 (1994).
102. Bucci, M. et al. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nature Med. 6, 1362-1367 (2000).
103. Catarina, R. D. et al. Nitric oxide decreases cytokine-induced endothelial activation. J. Clin. Invest. 96, 60-68 (1995).
104. Davenpeck, K. L., Gauthier, T. W. & Lefer, A. M. Inhibition of endothelial-derived nitric oxide promotes P-selectin expression and actions in the rat microcirculation. Gastroenterology 107, 1050-1058 (1994).
105. Kubes, P., Suzuki, M. & Granger, D. N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl Acad. Sci. USA 88, 4651-4655 (1991).
106. Lefer, D. J. et al. Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice. Am. J. Physiol. Heart Circ. Physiol. 276, H1943-H1950 (1999).
107. Fukumura, D. et al. Tumor necrosis factor α-induced leukocyte adhesion in normal and tumor vessels: Effect of tumor type, transplantation site, and host strain. Cancer Res. 55, 4824-4829 (1995).
108. Radomski, M. W., Palmer, R. M. & Moncada, S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc. Natl Acad. Sci. USA 87, 5193-5197 (1990).
109. Mehta, P. Potential role of platelets in the pathogenesis of tumor metastasis. Blood 63, 55-63 (1984).
110. Fukumura, D. et al. Role of nitric oxide in Kupffer cell-mediated hepatoma cell cytotoxicity in vitro and ex vivo. Hepatology 24, 141-149 (1996).
111. Wang, H. H. et al. B16 melanoma cell arrest in the mouse liver induces nitric oxide release and sinusoidal cytotoxicity: a natural hepatic defense against metastasis. Cancer Res. 60, 5862-5869 (2000).
112. Qiu, H. et al. Arrest of B16 melanoma cells in the mouse pulmonary microcirculation induces endothelial nitric oxide synthase-dependent nitric oxide release that is cytotoxic to the tumor cells. Am. J. Pathol. 162, 403-412 (2003).
113. Soler, M. N. et al. Gene therapy of rat medullary thyroid cancer by naked nitric oxide synthase II DNA injection. J. Gene Med. 2, 344-352 (2000).
114. Xu, W., Liu, L. & Charles, I. G. Microencapsulated iNOS-expressing cells cause tumor suppression in mice. FASEB J. 16, 213-215 (2002).
115. Singh, R., Pervin, S., Karimi, A., Cederbaum, S. & Chaudhuri, G. Arginase activity in human breast cancer cell lines: NA-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res. 60, 3305-3312 (2000).
116. Xie, K., Huang, S., Dong, Z., Gutman, M. & Fidler, I. J. Direct correlation between expression of endogenous inducible nitric oxide synthase and regression of M5076 reticulum cell sarcoma hepatic metastases in mice treated with liposomes containing lipopeptide CGP 31362. Cancer Res. 55, 3123-3131 (1995).
117. Onier, N. et al. Expression of inducible nitric oxide synthase in tumors in relation with their regression induced by lipid A in rats. Int. J. Cancer 81, 755-760 (1999).
118. Kundu, N. et al. Interleukin-10 gene transfer inhibits murine mammary tumors and elevates nitric oxide. Int. J. Cancer 76, 713-719 (1998).
119. Burdelya, L. et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J. Immunol. 174, 3925-3931 (2005).
120. Selleri, C. et al. Involvement of nitric oxide in farnesyltransferase inhibitor-mediated apoptosis in chronic myeloid leukemia cells. Blood 102, 1490-1498 (2003).
121. Simeone, A. M., Ekmekcioglu, S., Broemeling, L. D., Grimm, E. A. & Tari, A. M. A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide. Mol. Cancer Ther. 1, 1009-1017 (2002).
122. Binder, C., Schulz, M., Hiddemann, W. & Oellerich, M. Induction of inducible nitric oxide synthase is an essential part of tumor necrosis factor-α-induced apoptosis in MCF-7 and other epithelial tumor cells. Lab. Invest. 79, 1703-1712 (1999).
123. Edwards, P. et al. Tumor cell nitric oxide inhibits cell growth in vitro, but stimulates tumorigenesis and experimental lung metastasis in vivo. J. Surg. Res. 63, 49-52 (1996).
124. Harmey, J. H. et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int. J. Cancer 101, 415-422 (2002).
125. Mitchell, J. B. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res. 53, 5845-5848 (1993). Demonstration of radiosensitization by NO.
126. Cook, T. et al. Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53. Cancer Res. 64, 8015-8021 (2004).
127. Wang, Z. et al. Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vascularity. Cancer Res. 64, 1386-1395 (2004).
128. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005).
129. Jordan, B. F. et al. Nitric oxide as a radiosensitizer: Evidence for an intrinsic role in addition to its effect on oxygen delivery and consumption. Int. J. Cancer 109, 768-773 (2004).
130. Sonveaux, P. et al. Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radiosensitization and promotes gene delivery. FASEB J. 16, 1979-1981 (2002).
131. Thomsen, L. L. et al. Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor. Cancer Res. 57, 3300-3304 (1997).
132. Gallo, O. et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J. Natl Cancer Inst. 90, 584-596 (1998). Demonstration of anti-angiogenic effect of an NOS inhibitor on human tumour xenografts.
133. G-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am. J. Pathol. 155, 1381-1390 (1999).
134. Swaroop, G. R. et al. The effects of chronic nitric oxide synthase suppression on glioma pathophysiology. Br. J. Neurosurg. 14, 543-548 (2000).
135. Brouet, A. et al. Antitumor effects of in vivo caveolin gene delivery are associated with the inhibition of the proangiogenic and vasodilatory effects of nitric oxide. FASEB J. 19, 602-604 (2005).
136. Felley-Bosco, E., Bender, F. C., Courjault-Gautier, F., Bron, C. & Quest, A. F. Caveolin-1 down-regulates inducible nitric oxide synthase via the proteasome pathway in human colon carcinoma cells. Proc. Natl Acad. Sci. USA 97, 14334-14339 (2000).
137. Gratton, J. P., Bernatchez, P. & Sessa, W. C. Caveolae and caveolins in the cardiovascular system. Circ. Res. 94, 1408-1417 (2004).
138. Rao, C. V., Kawamori, T., Hamid, R. & Reddy, B. S. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis 20, 641-644 (1999).
139. Inano, H. & Onoda, M. Nitric oxide produced by inducible nitric oxide synthase is associated with mammary tumorigenesis in irradiated rats. Nitric Oxide 12, 15-20 (2005).
140. Khare, P. D. et al. Specifically targeted killing of carcinoembryonic antigen (CEA)-expressing cells by a retroviral vector displaying single-chain variable fragmented antibody to CEA and carrying the gene for inducible nitric oxide synthase. Cancer Res. 61, 370-375 (2001).
141. Cosby, K. et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nature Med. 9, 1498-1505 (2003). Demonstration of non-enzymatically produced NO and its physiological effect.
142. Sonveaux, P. et al. Oxygen regulation of tumor perfusion by S-nitrosohemoglobin reveals a pressor activity of nitric oxide. Circ. Res. 96, 1119-1126 (2005).
143. Galie, N. et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 353, 2148-2157 (2005).
144. Zhang, R. et al. Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat. Circ. Res. 92, 308-313 (2003).
145. Tozer, G. M. et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 61, 6413-6422 (2001).
146. Park, S. W. et al. The effect of nitric oxide on cyclooxygenase-2 (COX-2) overexpression in head and neck cancer cell lines. Int. J. Cancer 107, 729-738 (2003).
147. Kim, S. F., Huri, D. A. & Snyder, S. H. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 310, 1966-1970 (2005).
148. Cahlin, C. et al. Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids. Cancer Res. 60, 1742-1749 (2000).
149. Rigas, B. & Kashfi, K. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol. Med. 10, 324-330 (2004).
150. Ouyang, N. et al. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Res. 66, 4503-4511 (2006).
151. Cow, A. J., Farkouh, C. R., Munson, D. A., Posencheg, M. A. & Ischiropoulos, H. Biological significance of nitric oxide-mediated protein modifications. Am. J. Physiol. Lung Cell. Mol. Physiol. 287, L262-L268 (2004).
152. Rossig, L. et al. Nitric oxide inhibits caspase-3 by S-nitrosation in vivo. J. Biol. Chem. 274, 6823-6826 (1999).
153. Lander, H. et al. A molecular redox switch on p21ras. Structual Basis for the nitric oxide-p21 ras interaction. J. Biol. Chem. 272, 4323-4326 (1997).
154. Shizukuda, Y., Tang, S., Yokota, R. & Ware, J. A. Vascular endothelial growth factor-induced endothelial cell migration and proliferation depend on a nitric oxide-mediated decrease in protein kinase Cδ activity. Circ. Res. 85, 247-256 (1999).
155. Lopez-Rivera, E. et al. Matrix metalloproteinase 13 mediates nitric oxide activation of endothelial cell migration. Proc. Natl Acad. Sci. USA 102, 3685-3690 (2005).
156. Kojima, M. et al. Nitric oxide synthase expression and nitric oxide production in human colon carcinoma tissue. J. Surg. Oncol. 70, 222-229 (1999).
157. Kojima, H. et al. Development of a fluorescent indicator for nitric oxide based on the fluorescein chromophore. Chem. Pharm. Bull. 46, 373-375 (1998). Development of a fluorescent probe for NO.
158. Jain, R. K., Munn, L. L. & Fukumura, D. Dissecting tumour pathophysiology using intravital microscopy. Nature Rev. Cancer 2, 266-276 (2002).
159. Alitalo, K. & Carmeliet, P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1, 219-227 (2002).
160. Padera, T. P. et al. Cancer cells compress intratumour vessels. Nature 427, 695 (2004).
161. Padera, T. P. et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296, 1883-1886 (2002).
162. Franchi, A. et al. Inducible nitric oxide synthase activity correlates with lymphangiogenesis and vascular endothelial growth factor-C expression in head and neck squamous cell carcinoma. J. Pathol. 208, 439-445 (2006).
163. Nakamura, Y. et al. Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin. Cancer Res. 12, 1201-1207 (2006).
164. Hagendoorn, J., Padera, T. P., Fukumura, D. & Jain, R. K. Molecular regulation of microlymphatic formation and function: role of nitric oxide. Trends Cardiovasc. Med. 15, 169-173 (2005).
165. Hagendoorn, J. et al. Endothelial nitric oxide synthase regulates microlymphatic flow via collecting lymphatics. Circ. Res. 95, 204-209 (2004).
166. Witzenbichler, B. et al. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am. J. Pathol. 153, 381-394 (1998).
167. Makinen, T. et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 20, 4762-4773 (2001).
168. Shirasawa, Y., Ikomi, F. & Ohhashi, T. Physiological roles of endogenous nitric oxide in lymphatic pump activity of rat mesentery in vivo. Am. J. Physiol. Gastrointest. Liver Physiol. 278, G551-G556 (2000).